Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PFIZER INC. v. JOHNSON & JOHNSON et al
Case Number:
2:17-cv-04180
Court:
Nature of Suit:
Judge:
Firms
- Ballard Spahr
- Covington & Burling
- Cozen O'Connor
- Kenny Nachwalter
- Miller Shah LLP
- Munsch Hardt
- Patterson Belknap
- White & Case
- Zuckerman Spaeder
Companies
Sectors & Industries:
-
July 21, 2021
J&J Settles Pfizer's Antitrust Suit Over Remicade Biosimilar
Pfizer Inc. has agreed to drop its four-year-old suit alleging Johnson & Johnson violated antitrust laws by coercing health insurers into not covering biosimilar versions of J&J's inflammatory disease biologic Remicade, Pfizer confirmed to Law360 on Wednesday.
-
August 10, 2018
J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar
Pfizer Inc. has credibly shown that Johnson & Johnson may have flouted antitrust laws by coercing health insurers into not covering biosimilar versions of biologic Remicade, a Pennsylvania federal judge said in a ruling released Friday.
-
November 29, 2017
J&J Moves To Duck Pfizer Suit Over Remicade Biosimilar
Johnson & Johnson and its subsidiary Janssen Biotech Inc. urged a Pennsylvania federal court Tuesday to toss a suit brought by Pfizer Inc. alleging the companies used anti-competitive tactics to maintain the dominance of their biologic Remicade, saying Pfizer hasn't demonstrated the prices of its own biosimilar are competitive.
-
September 20, 2017
J&J Blocking Remicade Biosimilar Sales, Pfizer Says
Pfizer Inc. can't break into the market with its biosimilar version of Johnson & Johnson's blockbuster biologic Remicade, as J&J and its subsidiary Janssen Biotech Inc. have been holding on to a monopoly through a multifaceted anti-competitive campaign, Pfizer told a Pennsylvania federal court Wednesday.